GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Asset Impairment Charge

LTR Pharma (ASX:LTP) Asset Impairment Charge : A$0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Asset Impairment Charge?

LTR Pharma's Asset Impairment Charge for the six months ended in Jun. 2023 was A$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma Asset Impairment Charge Historical Data

The historical data trend for LTR Pharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Asset Impairment Charge Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Asset Impairment Charge
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Asset Impairment Charge - - -

LTR Pharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Asset Impairment Charge
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines